• Licensing and supervision
    • Brexit
    • Licensing of medicines
    • Authorisation procedures
    • Company authorisations and registrations
    • Supervision and inspection
    • Clinical trials
    • How to evaluate evidence of the efficacy of medicines
    • Evaluation of reviews
    • Report suspected illegal activities
    • Falsified medicines
    • Compassionate use
    • Medicine or not
    • Export certificates
    • Fees
    • Name/address changes
    • Relationships
    • Financial support
    • Medicinal Products Committee
    • Publications
  • Side effects and product information
    • Side effects of medicines
    • Additional monitoring
    • News on pharmacovigilance
    • Biological and biosimilar medicinal products
    • Safety updates
    • Post Authorisation Safety Study
    • Direct Healthcare Professional Communication
    • Adverse events
    • Drug interaction
    • Pharmacovigilance Council
    • Find medicines
    • Publications
  • Reimbursement and prices
    • General reimbursement
    • Individual reimbursement
    • Reimbursement thresholds
    • Medicines bought in another EU/EEA country
    • Reimbursement Committee
    • The EU HTA regulation
    • Prices of medicines
    • Product numbers
    • Central Reimbursement Register
    • Reimbursable nutritional products
    • Publications
  • Pharmacies and sale of medicines
    • Pharmacies
    • Sale outside pharmacies
    • Over-the-counter medicines
    • Substitution
    • Medicines imported from abroad
    • Buying and selling medicines online
    • Sale of medicines or food supplements online
    • Doctors buying medicines for use in their own practices
    • Report suspected illegal sale of medicines
    • Prescriptions from another country
    • Publications
  • Medical devices
    • Incident reporting
    • New regulations
    • COVID-19 antigen test for self-test
    • Advice to consumers on buying face masks
    • New Tech – new technological possibilities and medical devices
    • Interruption or discontinuation of the supply of medical devices
    • Patient safety and safe medical devices
    • Development of medical devices
    • Regulatory advice for medical device companies
    • CE marking
    • Notified bodies
    • Registration and marketing
    • Clinical investigations
    • Performance studies of in vitro diagnostic medical devices (IVDs)
    • Certificates of Free Sale
    • Legislation and guidance
    • Publications
  • Special product areas
    • Veterinary medicines
    • Natural medicinal products and vitamin and mineral products
    • Euphoriant substances
    • Medical gases
    • Radiopharmaceuticals
    • Medicines affecting the ability to drive
    • Medicinal cannabis
    • Regulation of innovative medicinal products including ATMP
  • About us
    • Mission, vision and strategy
    • Contact
    • Organisation
    • Whistleblowing scheme of the Danish Medicines Agency
    • The Danish Medicines Agency funding
    • Management of conflicts of interest
    • Transparency in the Danish Medicines Agency
    • Data protection policy
    • Targets and tasks
    • International collaboration
    • Jobs
    • Digital services
    • About this site
    • Social media
    • Design
    • Campaigns
    • Copyright
    • Cookies
    • Publications
    • Sitemap
  • News
    • Subscribe to news
    • Edit subscription
    • Unsubscribe
    • News categories
    • Themes
    • Our newsletter DKMA Update
    • RSS Feed
    • 2025
  • Publications
    • Order publications
    • 2025
    • 2024
    • 2023
    • 2022
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
    • 2011
    • 2010
    • 2009
    • 2008
    • 2007
    • 2006
Go to main content
  • News
  • About us
  • Contact us
  • Publications
  • Cookies
  • Licensing and supervision
    • Brexit
    • Licensing of medicines
    • Authorisation procedures
    • Company authorisations and registrations
    • Supervision and inspection
    • Clinical trials
    • How to evaluate evidence of the efficacy of medicines
    • Evaluation of reviews
    • Report suspected illegal activities
    • Falsified medicines
    • Compassionate use
    • Medicine or not
    • Export certificates
    • Fees
    • Name/address changes
    • Relationships
    • Financial support
    • Medicinal Products Committee
    • Publications
  • Side effects and product information
    • Side effects of medicines
    • Additional monitoring
    • News on pharmacovigilance
    • Biological and biosimilar medicinal products
    • Safety updates
    • Post Authorisation Safety Study
    • Direct Healthcare Professional Communication
    • Adverse events
    • Drug interaction
    • Pharmacovigilance Council
    • Find medicines
    • Publications
  • Reimbursement and prices
    • General reimbursement
    • Individual reimbursement
    • Reimbursement thresholds
    • Medicines bought in another EU/EEA country
    • Reimbursement Committee
    • The EU HTA regulation
    • Prices of medicines
    • Product numbers
    • Central Reimbursement Register
    • Reimbursable nutritional products
    • Publications
  • Pharmacies and sale of medicines
    • Pharmacies
    • Sale outside pharmacies
    • Over-the-counter medicines
    • Substitution
    • Medicines imported from abroad
    • Buying and selling medicines online
    • Sale of medicines or food supplements online
    • Doctors buying medicines for use in their own practices
    • Report suspected illegal sale of medicines
    • Prescriptions from another country
    • Publications
  • Medical devices
    • Incident reporting
    • New regulations
    • COVID-19 antigen test for self-test
    • Advice to consumers on buying face masks
    • New Tech – new technological possibilities and medical devices
    • Interruption or discontinuation of the supply of medical devices
    • Patient safety and safe medical devices
    • Development of medical devices
    • Regulatory advice for medical device companies
    • CE marking
    • Notified bodies
    • Registration and marketing
    • Clinical investigations
    • Performance studies of in vitro diagnostic medical devices (IVDs)
    • Certificates of Free Sale
    • Legislation and guidance
    • Publications
  • Special product areas
    • Veterinary medicines
    • Natural medicinal products and vitamin and mineral products
    • Euphoriant substances
    • Medical gases
    • Radiopharmaceuticals
    • Medicines affecting the ability to drive
    • Medicinal cannabis
    • Regulation of innovative medicinal products including ATMP
2016
News / 2016
News

You must accept marketing cookies to share the page by mail

Update consent

Share by mail

Verify you are a human

...

  • Danish Pharmacovigilance Update, November 2014

    | 02 December 2014 |

    Five years ago, we issued Danish Pharmacovigilance Update for the first time. We are delighted to celebrate the newsletter's fifth anniversary with more than 3,000 subscribers to the Danish and the English version, and we hope the interest in Danish Pharmacovigilance Update will continue to grow. You can sign up for the newsletter on our website under News. Among the articles in this issue, you can read about how we have developed the pharmacovigilance activities in the recent years.

  • Danish Pharmacovigilance Update, October 2014

    | 11 November 2014 |

    Read the October issue of Danish Pharmacovigilance Update.

  • Danish Pharmacovigilance Update, September 2014

    | 07 October 2014 |

    The September issue of Danish Pharmacovigilance Update.

  • Danish Pharmacovigilance Update, August 2014

    | 09 September 2014 |

    The August issue of Danish Pharmacovigilance Update.

  • Danish Pharmacovigilance Update June 2014

    | 17 July 2014 |

    The June issue of Danish Pharmacovigilance Update.

  • Danish Pharmacovigilance Update May 2014

    | 14 July 2014 |

    In the May issue of Danish Pharmacovigilance Update: Assessment of risk of serious anaphylactic reactions from treatment with ferumoxytol (Rienso), ADR reports for the HPV vaccine and the Danish Health and Medicines Authority’s annual pharmacovigilance report 2013.

  • Danish Pharmacovigilance Update 30 April 2014

    | 07 May 2014 |

    In the April issue of Danish Pharmacovigilance Update:

  • Danish Pharmacovigilance Update 29 January 2014

    | 14 April 2014 |

    In this issue of Danish Pharmacovigilance Update

  • Danish Pharmacovigilance Update 27 March 2014

    | 10 April 2014 |

    In this issue of Danish Pharmacovigilance Update

  • Danish Pharmacovigilance Update 27 February 2014

    | 01 April 2014 |

    In this issue of Danish Pharmacovigilance Update: Further restrictions on the use of osteoporosis medicine strontium ranelate (Protelos®), Anticoagulant therapy to be stopped before initiating treatment with the new oral anticoagulants (NOACs).

  • Danish Pharmacovigilance Update 31 October 2013

    | 05 March 2014 |

    In this issue of Danish Pharmacovigilance Update: The risk of blood clots from the use of contraceptive pills is low regardless of type, Report of cardiac arrest in association with the use of flecainide (Tambocor®).

  • Danish Pharmacovigilance Update 19 December 2013

    | 17 February 2014 |

    In this issue of Danish Pharmacovigilance Update: Patients with mechanical heart valves should not be treated with the new oral anticoagulants Pradaxa®, Xarelto® and Eliquis®.

  • Danish Pharmacovigilance Update 28 November 2013

    | 03 February 2014 |

    In this issue of Danish Pharmacovigilance Update: Ciprofloxacin and the risk of tendon disorders, risk of blood clots from the use of the cancer medicine ponatinib and reporting of adverse reactions to the Danish Health and Medicines Authority.

All items (479)
  • Time

    • 2025 (10)
    • 2024 (26)
    • 2023 (24)
    • 2022 (20)
    • 2021 (44)
    • 2020 (62)
    • 2019 (20)
    • 2018 (37)
    • 2017 (54)
    • 2016 (53)
    • 2015 (11)
    • 2014 (13)
      • December (1)
      • November (1)
      • October (1)
      • September (1)
      • July (2)
      • May (1)
      • April (3)
      • March (1)
      • February (2)
    • 2013 (11)
    • 2012 (11)
    • 2011 (13)
    • 2010 (9)
    • 2009 (14)
    • 2008 (7)
    • 2007 (3)
    • 2006 (10)
footer-logo

Danish Medicines Agency

Axel Heides Gade 1

2300 København S

Email: dkma@dkma.dk


The Danish Medicines Agency is part of the
Ministry of Interior and Health.

Contact the Danish Medicines Agency

+45 44 88 95 95 (9am - 3pm)

Follow us

  • facebook logo
  • LinkedIn
  • RSS

CVR-nr. 37 05 24 85

EAN 5798 000 36 33 66

Privacy policy Cookie policy